… VT3989 Pipeline Update The FDA granted fast track designation … #47;2 Trial? This multicenter, open-label trial is enrolling … plus nivolumab (Opdivo) or ipilimumab (Yervoy). Cohort B will … us-food-and-drug-administration-for-the-treatment-of-mesothelioma- …

… patients who responded to treatment, three experienced biopsy- … Phase I dose escalation trial. This will be … drug, Keytruda (pembrolizumab) and BMS’ Opdivo (nivolumab) plus Yervoy (ipilimumab). … deserve! The Clinical Trials Arena Excellence Awards celebrate …

… protocol-assigned study medication at 48 months … or emerge after treatment continuation, investigators evaluated … discontinuation of study drug or reported after … trial in which patients with advanced melanoma receiving combination nivolumab plus ipilimumab …

… treatment of different types of immunotherapies, including pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab … Medical Oncology. Efficacy Observed Across Key Trials … drug regimen. The phase 3 CheckMate 9LA trial … [doctor] be aware. Radiation Treatment Kim …

… clinical trial provided new insight into first-line treatment for … and PD-1 inhibitors (ipilimumab and nivolumab) to various … to standard-of-care treatments (68%). Secondary outcomes … and toxicity leading to treatment discontinuation occurred more frequently …

… drugs.  Key advanced liver cancer companies such as Polaris Pharmaceuticals, Shanghai Henlius Biotech … advanced liver cancer clinical trials. In June 2025, … III trial for the first-line treatment of … or nivolumab plus ipilimumab offering meaningful survival …

… renal cell carcinoma present unique treatment challenges requiring careful consideration of … years has transformed favorable-risk treatment paradigms. Tykodi emphasizes reduced … risk patients initially showed an ipilimumab plus nivolumab disadvantage, but …

… resists conventional treatments. Microcatheter-assisted drug-loaded microspheres … trial assessed the efficacy of nivolumab combined with ipilimumab … doi:10.3390/pharmaceutics14020359. 10. Nicoletti R, … al. Intradermal DNA vaccination combined with dual CTLA …

… Reserve University School of Medicine, and director of the … the LEAP-002 trial (NCT03713593). In both trials, the median overall … in ipilimumab/nivolumab becoming an approved first-line treatment in … be using a particular drug, and in this particular …

… timely, confident, and data-driven treatment decisions when every moment counts … phase 3 trial supported the FDA approval of nivolumab plus ipilimumab in patients … Hersey, vice president of Precision Medicine, Bioanalytical and Translational Sciences at …